Anne Odonnell-Luria

Anne Odonnell-Luria

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Anne Odonnell-Luria

Center for Genomic Medicine, Massachusetts General Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Nature
Verified
Journal Article
Open access
PDF file
KKKonrad J. Karczewski
Konrad J. Karczewski
LFLaurent C. Francioli
Laurent C. Francioli
GTGrace Tiao
Grace Tiao
BCBeryl B. Cummings
Beryl B. Cummings
JAJessica Alföldi
Jessica Alföldi
DMDaniel G. MacArthur
Daniel G. MacArthur
Genetic variants that inactivate protein-coding genes are a powerful source of information about the phenotypic consequences of gene disruption: genes that are crucial for the function of an organism will be depleted of such variants in natural populations, whereas non-essential genes will tolerate their accumulation. However, predicted loss-of-function variants are enriched for annotation errors, and tend to be found at extremely low frequencies, so their analysis requires careful variant annotation and very large sample sizes1. Here we describe the aggregation of 125,748 exomes and 15,708 genomes from human sequencing studies into the Genome Aggregation Database (gnomAD). We identify 443,769 high-confidence predicted loss-of-function variants in this cohort after filtering for artefacts caused by sequencing and annotation errors. Using an improved model of human mutation rates, we classify human protein-coding genes along a spectrum that represents tolerance to inactivation, validate this classification using data from model organisms and engineered human cells, and show that it can be used to improve the power of gene discovery for both common and rare diseases.

17 August 2016 in Nature
Verified
Journal Article
Open access
PDF file
ECExome Aggregation Consortium
Exome Aggregation Consortium
MLMonkol Lek
Monkol Lek
KKKonrad J. Karczewski
Konrad J. Karczewski
EMEric Vallabh Minikel
Eric Vallabh Minikel
KSKaitlin E. Samocha
Kaitlin E. Samocha
DMDaniel G. MacArthur
Daniel G. MacArthur
Large-scale reference data sets of human genetic variation are critical for the medical and functional interpretation of DNA sequence changes. Here we describe the aggregation and analysis of high-quality exome (protein-coding region) DNA sequence data for 60,706 individuals of diverse ancestries generated as part of the Exome Aggregation Consortium (ExAC). This catalogue of human genetic diversity contains an average of one variant every eight bases of the exome, and provides direct evidence for the presence of widespread mutational recurrence. We have used this catalogue to calculate objective metrics of pathogenicity for sequence variants, and to identify genes subject to strong selection against various classes of mutation; identifying 3,230 genes with near-complete depletion of predicted protein-truncating variants, with 72% of these genes having no currently established human disease phenotype. Finally, we demonstrate that these data can be used for the efficient filtering of candidate disease-causing variants, and for the discovery of human ‘knockout’ variants in protein-coding genes.

6 December 2023 in Nature
Verified
Journal Article
Closed access
PDF file
SCSiwei Chen
Siwei Chen
LFLaurent C. Francioli
Laurent C. Francioli
JGJulia K. Goodrich
Julia K. Goodrich
RCRyan L. Collins
Ryan L. Collins
MKMasahiro Kanai
Masahiro Kanai
KKKonrad J. Karczewski
Konrad J. Karczewski

27 May 2020 in Nature
Verified
Journal Article
Open access
PDF file
RCRyan L. Collins
Ryan L. Collins
HBHarrison Brand
Harrison Brand
KKKonrad J. Karczewski
Konrad J. Karczewski
XZXuefang Zhao
Xuefang Zhao
JAJessica Alföldi
Jessica Alföldi
MTMichael E. Talkowski
Michael E. Talkowski
Structural variants (SVs) rearrange large segments of DNA1 and can have profound consequences in evolution and human disease2,3. As national biobanks, disease-association studies, and clinical genetic testing have grown increasingly reliant on genome sequencing, population references such as the Genome Aggregation Database (gnomAD)4 have become integral in the interpretation of single-nucleotide variants (SNVs)5. However, there are no reference maps of SVs from high-coverage genome sequencing comparable to those for SNVs. Here we present a reference of sequence-resolved SVs constructed from 14,891 genomes across diverse global populations (54% non-European) in gnomAD. We discovered a rich and complex landscape of 433,371 SVs, from which we estimate that SVs are responsible for 25–29% of all rare protein-truncating events per genome. We found strong correlations between natural selection against damaging SNVs and rare SVs that disrupt or duplicate protein-coding sequence, which suggests that genes that are highly intolerant to loss-of-function are also sensitive to increased dosage6. We also uncovered modest selection against noncoding SVs in cis-regulatory elements, although selection against protein-truncating SVs was stronger than all noncoding effects. Finally, we identified very large (over one megabase), rare SVs in 3.9% of samples, and estimate that 0.13% of individuals may carry an SV that meets the existing criteria for clinically important incidental findings7. This SV resource is freely distributed via the gnomAD browser8 and will have broad utility in population genetics, disease-association studies, and diagnostic screening.

2 December 2021 in Human Mutation
Verified
Journal Article
Open access
PDF file
SGSanna Gudmundsson
Sanna Gudmundsson
MSMoriel Singer‐Berk
Moriel Singer‐Berk
NWNicholas A. Watts
Nicholas A. Watts
WPWilliam Phu
William Phu
JGJulia K. Goodrich
Julia K. Goodrich
AOAnne O'Donnell‐Luria
Anne O'Donnell‐Luria
Reference population databases are an essential tool in variant and gene interpretation. Their use guides the identification of pathogenic variants amidst the sea of benign variation present in every human genome, and supports the discovery of new disease-gene relationships. The Genome Aggregation Database (gnomAD) is currently the largest and most widely used publicly available collection of population variation from harmonized sequencing data. The data is available through the online gnomAD browser (https://gnomad.broadinstitute.org/) that enables rapid and intuitive variant analysis. This review provides guidance on the content of the gnomAD browser, and its usage for variant and gene interpretation. We introduce key features including allele frequency, per-base expression levels, constraint scores, and variant co-occurrence, alongside guidance on how to use these in analysis, with a focus on the interpretation of candidate variants and novel genes in rare disease.

19 April 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BCBeryl B. Cummings
Beryl B. Cummings
JMJamie L. Marshall
Jamie L. Marshall
TTTaru Tukiainen
Taru Tukiainen
MLMonkol Lek
Monkol Lek
SDSandra Donkervoort
Sandra Donkervoort
DMDaniel G. MacArthur
Daniel G. MacArthur
Exome and whole-genome sequencing are becoming increasingly routine approaches in Mendelian disease diagnosis. Despite their success, the current diagnostic rate for genomic analyses across a variety of rare diseases is approximately 25 to 50%. We explore the utility of transcriptome sequencing [RNA sequencing (RNA-seq)] as a complementary diagnostic tool in a cohort of 50 patients with genetically undiagnosed rare muscle disorders. We describe an integrated approach to analyze patient muscle RNA-seq, leveraging an analysis framework focused on the detection of transcript-level changes that are unique to the patient compared to more than 180 control skeletal muscle samples. We demonstrate the power of RNA-seq to validate candidate splice-disrupting mutations and to identify splice-altering variants in both exonic and deep intronic regions, yielding an overall diagnosis rate of 35%. We also report the discovery of a highly recurrent de novo intronic mutation in COL6A1 that results in a dominantly acting splice-gain event, disrupting the critical glycine repeat motif of the triple helical domain. We identify this pathogenic variant in a total of 27 genetically unsolved patients in an external collagen VI–like dystrophy cohort, thus explaining approximately 25% of patients clinically suggestive of having collagen VI dystrophy in whom prior genetic analysis is negative. Overall, this study represents a large systematic application of transcriptome sequencing to rare disease diagnosis and highlights its utility for the detection and interpretation of variants missed by current standard diagnostic approaches.